Let’s talk about how we can work together to advance bioengineering.
Nanoparticles designed with complementary chemical and mechanical forces improve the targeting of tumors with cancer-fighting drugs.
Gain access to free tools and resources from AABME, an initiative designed to stimulate biomedical innovation by bringing together and providing resources to the biomedical engineering community.
An artificial pancreas that releases both insulin and pramlintide, an analog of amylin, might offer better control during the after-meal period.
Engineers have developed a new process of 3D bioprinting tissues that uses multiple cell-based inks to create more realistic structures in less time than previous methods.
A new device from scientists at McGill University’s Department of Bioengineering allows early and quick detection of life-threatening bacteria.
A great idea doesn't always translate to a successful product. In this webinar, hear from Tiffany Wilson, who has spent years advancing innovative medical technology from benchtop to bedside, as she share the common pitfalls in product development.
The first viable prototype of an artificial lung offers new hope for the more than one thousand people awaiting lung transplants across the United States.
A low-cost haptic needle simulator aims to train young minds without expensive equipment.
Genome editing, or genome engineering is a type of genetic engineering in which DNA is inserted, deleted, modified or replaced in the genome of a living organism. Attend this webinar, moderated by Gang Bao, and understand the differences between three technologies.
Barcoded nanoparticles deliver nucleic acids to treat cancer, viral infections, and neurodegenerative diseases.
A new approach to finding drug candidates for fighting cancers can drastically cut the time and money needed to evaluate millions of them.
Surgeons could torch tumors faster and more accurately with help from a new thermal imaging system.
Researchers have improved the ability of cancer-killing T-cells to target pancreatic tumors rather than healthy tissue by engineering the cells to produce more receptors.
Traditionally, innovation has started with technology looking for a need. However, the complexities and variety of stakeholders involved in commercialization in biomedical technology call for a different approach - to lead with the need.